Genetic Mapping of the Camurati-Engelmann Disease Locus to Chromosome 19q13.1-q13.3  by Ghadami, Mohsen et al.
Am. J. Hum. Genet. 66:143–147, 2000
143
Genetic Mapping of the Camurati-Engelmann Disease Locus to
Chromosome 19q13.1-q13.3
Mohsen Ghadami,1 Yoshio Makita,4 Kunihiro Yoshida,5 Gen Nishimura,7
Yoshimitsu Fukushima,6 Keiko Wakui,6 Shiro Ikegawa,8 Koki Yamada,1,2
Shinji Kondo,1,3 Norio Niikawa,1 and Hiro-aki Tomita1
Departments of 1Human Genetics, 2Ophthalmology, and 3Plastic Surgery, Nagasaki University School of Medicine, Nagasaki; 4Department of
Pediatrics and Public Health, Asahikawa Medical College, Asahikawa, Japan; 5Third Department of Internal Medicine and 6Department of
Hygiene and Medical Genetics, Shinshu University School of Medicine, Matsumoto, Japan; and 7Department of Radiology, Nishi-Tama
Hospital, and 8Human Genome Center, University of Tokyo, Tokyo
Summary
Camurati-Engelmann disease (CED [MIM 131300]), or
progressive diaphyseal dysplasia, is an autosomal dom-
inant sclerosing bone dysplasia characterized by pro-
gressive bone formation along the periosteal and en-
dosteal surfaces at the diaphyseal and metaphyseal
regions of long bones and cranial hyperostosis, partic-
ularly at the skull base. The gene for CED, or its chro-
mosomal localization, has not yet been identified. We
performed a genomewide linkage analysis of two un-
related Japanese families with CED, in which a total of
27 members were available for this study; 16 of them
were affected with the disease. Two-point linkage anal-
ysis revealed a maximum LOD score of 7.41 (recom-
bination fraction .00; penetrance 1.00) for theD19S918
microsatellite marker locus. Haplotype analysis revealed
that all the affected individuals shared a common hap-
lotype observed, in each family, between D19S881 and
D19S606, at chromosome 19q13.1-q13.3. These find-
ings, together with a genetic distance among the marker
loci, indicate that the CED locus can be assigned to a
15.1-cM segment between D19S881 and D19S606.
Introduction
Camurati-Engelmann disease (CED [MIM 131300]),
or progressive diaphyseal dysplasia, is an osteosclerotic
dysplasia characterized by symmetrical hyperostosis in-
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itiating at the diaphyses of the long tubular bones, usu-
ally of the femora or tibiae, and expanding to their meta-
physes and to membranous bones. The hyperostosis of
the skull base occasionally leads to cranial nerve palsy.
The onset of the disease is often during early childhood
and almost always at age !30 years. Radiographic ab-
normalities include diaphyseal cortical thickening, peri-
osteal and endosteal sclerosis of the long bones, and
basal skull sclerosis. Patients with CED have severe pain
in the legs, muscle weakness, a waddling gait, and easy
fatigability and occasionally suffer from systemic man-
ifestations, such as anemia, leukopenia, or hepatosplen-
omegaly (Crisp and Brenton 1982). No specific labo-
ratory findings for the disease have been identified,
although a raised erythrocyte-sedimentation rate, an in-
creased level of serum alkaline phosphatase, increased
urinary excretion of hydroxyproline, or a reduced level
of hematocrit or hemoglobin have been reported in some
patients (Hundley and Wilson 1973; Smith et al. 1977;
Crisp and Brenton 1982). Pollack et al. (1989) reported
that all the patients examined by them had markedly
elevated proportions of OKM1-positive mononuclear
cells and that some of the healthy relatives also exhibited
the same abnormality. Therapy with a prolonged low
dosage of corticosteroid hormone is effective not only
in relieving the pain but also in reversing the radiological
findings, although the mechanism through which ster-
oids act remains undefined (Minford et al 1981). Re-
ported histopathological findings, although they are con-
troversial, include altered bone cortex, with progressive
active bone resorption as well as deposition (Rubin
1964); the absence of osteoclasts in the bone lesions,
which recovered after steroid treatment leading to in-
creased bone absorption and secondary remodeling (Al-
len et al. 1970); and thickening of the blood-vessel wall
in the bone (Rubin 1964) and skeletal muscles (Yoshioka
et al. 1980; Naveh et al. 1985). Diagnosis is based on
these clinical, radiographic, and/or pathological mani-
festations. More than 100 patients with CED have been
reported in the literature, and the prevalence of CED is
144 Am. J. Hum. Genet. 66:143–147, 2000
estimated to be !1/1 million (Wynne-Davies et al. 1985).
Both sporadic and familial cases have been described.
In familial cases, the disease is inherited in an autosomal
dominant mode with incomplete penetrance and vari-
able expression (Sparkes and Graham 1972). Here we
report the result of a genetic linkage analysis of two
unrelated Japanese families with CED.
Subjects and Methods
Families and Patients
Two unrelated Japanese families (families 1 and 2)
were analyzed in the present study. A total of 27 mem-
bers of the two families agreed to participate in the pres-
ent study, with written informed consent. Of the 27
members, 16 were diagnosed as having CED (fig. 1), on
the basis of clinical and radiographic findings—that is,
continuous disabling pain in the legs, muscle weakness
with waddling gait, diaphyseal cortical fusiform thick-
ening, and periosteal and endosteal sclerosis of the long
bones. Detailed clinical data on affected members of
family 1 have been reported elsewhere (Makita et al., in
press). The proband in family 2 (I-3; see fig. 1) was a
48-year-old woman with complaints of upper- and
lower-limb pain, easy fatigability, muscle weakness, and
waddling gait. Onset of her disease was at age 3 years.
The findings of radiographic survey and 99mTc-MDP
bone scintigraphy were consistent with CED. Three of
her four children are also affected with CED (fig. 1).
Genotyping and Linkage Analysis
Genomic DNA samples were collected from the 27
available individuals in the two families. Highly poly-
morphic microsatellite markers were chosen from the
Ge´ne´thon database (Dib et al. 1996), and their corre-
sponding primer sets were synthesized. The forward
primer of each set was labeled with fluorescent dye (Cy5;
Pharmacia Biotech), and the reverse primer was not la-
beled. For the chromosomal assignment of the disease
locus, we adopted a two-step analysis. In the first step,
we performed a genomewide linkage analysis using
markers distributed across the genome that were sepa-
rated by an average distance of ∼10 cM. When prelim-
inary data for assignment to a chromosomal region were
obtained, we analyzed additional markers to confirm the
linkage and to delimit the CED critical region (CEDR)
(fig. 1).
PCR amplification was performed in a 12.5-ml reac-
tion mixture containing 50 ng of genomic DNA, 1–3
mM MgCl2, 0.2 mM of each deoxynucleotide triphos-
phate, 0.5 U of DNA polymerase (AmpliTaq Gold; PE
Biosystems), and 12.5 pmol of each primer. PCR con-
ditions consisted of an initial denaturation at 94C for
10 min; 40 cycles of denaturation at 94C for 30 s,
annealing at 48–58C for 30 s, and extension at 72C
for 30 s; and final extension at 72C for 10 min. PCR
products were resolved by electrophoresis on 6% poly-
acrylamide DNA sequencing gel, by use of an automated
sequencer (ALFexpress; Pharmacia Biotech). Electro-
phoretic patterns were analyzed by computer software
(Fragment Manager; Pharmacia Biotech), to determine
the genotypes of the family members.
Two-point linkage analysis was performed by the
computer program MLINK of the FASTLINK software,
version 4.0P (Lathrop et al. 1984; Cottingham et al.
1993; Scha¨ffer et al. 1994), under the assumption that
CED in the two families is inherited in an autosomal
dominant mode, with a disease-gene frequency of
.000001 (Wynne-Davies et al. 1985). Equal allele fre-
quencies were used for all marker loci. However, the
allele frequency for each of five markers (D19S422,
D19S223, D19S918, D19S902, and D19S606) around
the CEDR was calculated in 80 chromosomes from un-
related healthy Japanese individuals.
Results
Since samples were collected earlier from family 1 and
since it is larger than family 2, we first undertook a
genomewide search in family 1. A maximum two-point
LOD score ( at recombination fraction [v]Z = 6.20max
.00) was obtained at the D19S918 locus when pene-
trance (p) was assumed to be 1.0.We chose 23 additional
markers (16 markers centromeric to and 7 telomeric to
D19S918) that are located around D19S918, to analyze
family 1. Haplotype analysis of family 1 demonstrated
that all the affected members had a common haplotype
between D19S881 and D19S606, including 15 markers
(fig. 1). Recombinations had occurred four times in three
affected members: one betweenD19S422 andD19S223
in individual II-2, one between D19S219 and D19S606
in II-10, and two (double recombination), between
D19S414 and D19S570 and between D19S881 and
D19S211, in III-9 (fig. 1). Thus, most of the region as-
sociated with CED lies betweenD19S881 andD19S606.
We then extended the analysis with the same markers
to family 2 and confirmed a linkage of the disease to
the same chromosomal region between D19S881 and
D19S606 (fig. 1). There was one recombination between
D19S606 and D19S867 in individual II-3 in this family.
Results for this family, however, did not allow us to
narrow the linked segment.
The two-pointZmax calculated for the two families was
7.41, for D19S918, at ( ) (table 1). Inv = .00 p = 1.00
light of the genetic distance between the markers used,
the CEDR lies in a 15.1-cM segment between D19S881
andD19S606, at 19q13.1-q13.3 (GenomeDatabase [Ja-
pan]; Human Genome Resources) (fig. 1).
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Table 1
Two-Point LOD Scores of CED in the Two Families, at
Representative Marker Loci at 19q13.1-q13.3, with
Representative p Values
LOCUS AND p
LOD SCORE AT v=
.00 .001 .05 .1 .15 .2
D19S422:
1.0  3.38 .01 .50 .68 .71
.8 7.13 3.52 .17 .31 .49 .54
D19S223:
1.0 3.60 3.59 3.25 2.88 2.50 2.11
.8 3.13 3.12 2.81 2.48 2.13 1.79
D19S211:
1.0 5.44 5.44 5.14 4.73 4.27 3.75
.8 5.03 5.03 4.65 4.22 3.77 3.28
D19S913:
1.0 4.92 4.91 4.65 3.99 3.49 2.97
.8 4.37 4.36 3.95 3.50 3.05 2.58
D19S408:
1.0 4.22 4.22 4.08 3.81 3.45 3.03
.8 4.09 4.09 3.80 3.46 3.08 2.67
D19S217:
1.0 5.84 5.84 5.36 4.82 4.24 3.62
.8 5.18 5.18 4.70 4.19 3.65 3.08
D19S918:
1.0 7.41 7.39 6.77 6.10 5.44 4.67
.8 6.55 6.54 5.96 5.35 4.72 4.06
D19S219:
1.0 4.25 4.24 3.90 3.52 3.12 2.68
.8 3.94 3.93 3.59 3.23 2.83 2.41
D19S902:
1.0 2.54 2.54 2.32 2.07 1.80 1.52
.8 2.28 2.27 2.06 1.82 1.58 1.33
D19S606:
1.0  .23 1.68 1.71 1.60 1.41
.8 2.34 .02 1.43 1.47 1.37 1.21
Discussion
It has been documented that CED is inherited in an
autosomal dominant fashion with incomplete pene-
trance and variable expressivity (Sparkes and Graham
1972). The two families examined in the present study
showed complete penetrance, although expressivity was
very variable in family 1. In family 1, 5 of the 12 affected
members had clinical manifestations milder than those
seen in the other 7, and the age at disease onset among
these 12 members varied from age 3 years to the late
20s. An 8-year-old boy (III-2) and a 25-year-old man
(III-7) in the family did not present any clinical symp-
toms of CED (Makita et al., in press) but were found
to have both periosteal sclerosis of the fibula and the
disease-associated haplotype (fig. 1). Thus, penetrance
was complete in this family, when an extensive radio-
graphic survey was performed in the two asymptomatic
patients. The highly variable expressivity of the disorder
may explain why “incomplete penetrance” has been pro-
posed, and why “autosomal recessive inheritance” has
been considered in some families (Hundley and Wilson
1973). Clybouw et al. (1994) reported a family in which
the mother of a patient with CED had no abnormal
clinical findings but showed, on 99mTc-scintigraphy, in-
creased osteoblastic activity in the diaphyseal portions
of almost all long bones, and they suggested the necessity
of detailed radiographic examinations to diagnose CED.
Phenotypes of five affected members of family 1 were
reminiscent of Ribbing disease, as suggested by Makita
et al. (in press).
The region of 19q13.1-q13.3 defined as the CEDR is
a gene-rich region to which several genes, skeletal tis-
sue–derived expressed-sequence tags, or bone dyspla-
sia–related disease loci have been mapped. Among them,
the genes for calmodulin 3 (CALM3) (Berchtold et al.
1993), zinc-finger protein 36 (ZFP36) (Taylor et al.
1991), and transforming growth-factor beta 1 (TGFB1)
(Fujii et al. 1986) merit comments. CALM3 encodes a
calcium-modulated protein; ZNF36 is the gene for a
zinc-finger protein, and ZNF36-deficient mice are born
as normal neonates but soon develop a complex syn-
drome of inflammatory arthritis, dermatitis, cachexia,
autoimmunity, and myeloid hyperplasia; andTGFB1 en-
codes a member of the TGF-b superfamily. Since a high
level of the TGFB1 message appears in both osteoblasts
and osteoclasts of the developing bone, as well as in the
periosteal fibroblasts and bone marrow cells, TGFB1
may play an important role in postnatal bone devel-
opment (Sandberg et al. 1988a, 1988b).Tgfb1 knockout
(Tgfb1/) mice show decreased mineral content in the
proximal tibial metaphyses—as evidenced in the width
of the tibial growth plate and the longitudinal growth
rate—as well as various systemic manifestations, al-
though the heterozygous (Tgfb1/) mice shownormal
bone development (Geiser et al. 1998). It remains to be
seen whether any of these genes, especially TGFB1, are
causally related to CED.
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